Abstract | PURPOSE: To determine if inhibitors of the human growth factor receptor (HER) family can be used to enhance tumor vascular permeability and perfusion and optimize the efficacy of cytotoxic chemotherapeutics. Poor tumor vascular function limits the delivery and efficacy of cancer chemotherapeutics and HER family tyrosine kinases mediate tumor-endothelial signaling in both of these compartments. MATERIALS AND METHODS: RESULTS: A brief dose of gefitinib enhances the antitumor activity of paclitaxel in vivo but not in cell culture, suggesting that its chemoenhancing activity involves the in vivo microenvironment. A brief high dose of gefitinib induces a decrease in endothelial transfer constant (Kps) and a concomitant increase in tumor fractional plasma volume (fPV). These changes are accompanied by a rapid reduction in tumor volume, likely due to decreased tumor edema, and modestly improved tumor vascular architecture and perfusion on microscopy. CONCLUSION: These data suggest that HER family TKIs have the potential to optimize the tumor microenvironment for delivery of cytotoxic chemotherapeutics.
|
Authors | Mark M Moasser, Lisa J Wilmes, Ching Hang Wong, Sheye Aliu, Ka-Loh Li, Donghui Wang, Yun Kit Hom, Byron Hann, Nola M Hylton |
Journal | Journal of magnetic resonance imaging : JMRI
(J Magn Reson Imaging)
Vol. 26
Issue 6
Pg. 1618-25
(Dec 2007)
ISSN: 1053-1807 [Print] United States |
PMID | 17968965
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | (c) 2007 Wiley-Liss, Inc. |
Chemical References |
- Antineoplastic Agents
- Contrast Media
- Quinazolines
- Receptors, Vascular Endothelial Growth Factor
- Gadolinium DTPA
- Gefitinib
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Breast Neoplasms
(blood supply, drug therapy, pathology)
- Capillary Permeability
(drug effects)
- Contrast Media
- Gadolinium DTPA
- Gefitinib
- Magnetic Resonance Imaging
(methods)
- Mice
- Mice, Nude
- Neovascularization, Pathologic
(pathology)
- Quinazolines
(pharmacology)
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors)
|